Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

59.29 -1.90 (-3.11%)
Streaming Delayed Price Updated: 3:36 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
33 34 Next >
The Latest Analyst Ratings for CRISPR Therapeutics
 
Via Benzinga
CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases
Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T  
Via Benzinga
Better Growth Stock: CRISPR Therapeutics vs. Invitae
One of these stocks may be riskier than the other... 
Via The Motley Fool
The Market's Up This Year. Do You Feel Like You Are Winning?
We've also got a look at two stocks worth watching and the popular toys for this holiday season. 
Via The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
Is CRISPR Therapeutics the Best Gene-Editing Stock?
The biotech's first-mover advantage bodes well for its long-term prospects. 
Via The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex shares have soared 400% over the past decade. 
Via The Motley Fool
If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today
CRISPR Therapeutics' shares advanced in the double-digits this year. 
Via The Motley Fool
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
The one thing these two stocks have in common is tremendous growth prospects. 
Via The Motley Fool
An Important History Lesson for Gene-Editing Investors
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy. 
Via The Motley Fool
5 Top Stocks to Buy Before 2024
These stocks have room to run -- next year and over the long term. 
Via The Motley Fool
Five Best Performing Stocks Of The Top ETF Of November
Most stocks in ARKK’s portfolio delivered strong returns in November. These five led the way. 
Via Talk Markets
Topics ETFs
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
It's not as long a shot as some might think. 
Via The Motley Fool
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist
These stocks offer enormous long-term growth potential. 
Via The Motley Fool
3 Biotech Stocks That Could Be Multibaggers in the Making
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception
The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014. 
Via Benzinga
Topics ETFs
Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here. 
Via Benzinga
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies. 
Via InvestorPlace
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market
These stocks may take off in a market favoring growth. 
Via The Motley Fool
Investing in These 3 Stocks Now Could Make You a Millionaire Retiree
These innovators should have tremendous long-term growth prospects. 
Via The Motley Fool
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
What's Going On With Crispr Therapeutics Stock Monday?
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday on what appears to be continued momentum from the recent regulatory authorization of the company's  
Via Benzinga
Google’s Bard AI Says These 3 Stocks Will Rise 1,000%
Google's Bard has been among the best stock pickers, and thinks these three stocks have quadruple-digit upside potential. 
Via InvestorPlace
Topics Artificial Intelligence
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio? 
Via The Motley Fool
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
The stock is trading below its peak, reached a couple of years ago. 
Via The Motley Fool
3 Monster Stocks in the Making
These stocks could grow much larger over the next few years. 
Via The Motley Fool
Why CRISPR Therapeutics Stock Is Jumping Again Today
The stock continues to enjoy momentum from a key regulatory approval. 
Via The Motley Fool
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. 
Via Benzinga
Topics Stocks
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News
CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.